A Phase I trial and PK Study of Cediranib (AZD2171), an Orally Bioavailable Pan-VEGFR Inhibitor, in Children with Recurrent or Refractory Primary CNS Tumors

BACKGROUND: Cediranib (AZD2171), an oral, pan VEGF inhibitor, was evaluated in this phase I study to determine its toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics, in children and adolescents with recurrent or refractory primary...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Childs Nerv Syst
Main Authors: Kieran, Mark W., Chi, Susan, Goldman, Stewart, Onar-Thomas, Arzu, Poussaint, Tina Young, Vajapeyam, Sridhar, Fahey, Frederic, Wu, Shengjie, Turner, David C., Stewart, Clinton F., Moses, Marsha, Packer, Roger J., Jakacki, Regina, Banerjee, Anu, Boyett, James M., Fouladi, Maryam, Kun, Larry
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4561207/
https://ncbi.nlm.nih.gov/pubmed/26188774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00381-015-2812-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados